| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8443465 | European Journal of Cancer | 2014 | 8 Pages |
Abstract
The PSA response to cabazitaxel, with or without initial flare, was associated with a strong survival benefit. The taxane-induced flare during the first 12Â weeks of therapy can be ignored when evaluating PSA response.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Antoine Angelergues, Denis Maillet, Aude Fléchon, Mustafa Ozgüroglu, Florence Mercier, Aline Guillot, Sylvestre Le Moulec, Gwenaelle Gravis, Philippe Beuzeboc, Christophe Massard, Karim Fizazi, Thibault de La Motte Rouge, Nicolas Delanoy,